Previous 10 | Next 10 |
home / stock / mnkkq / mnkkq news
Mallinckrodt (MNKKQ) announces publication of results from Phase 3 STRATA2016 trial of StrataGraft in a peer-reviewed journal, Burns.The trial, which evaluated the efficacy and safety of a single application of StrataGraft in adult patients with deep partial-thickness thermal burns, achi...
Mallinckrodt Announces Publication of Phase 3 STRATA2016 Study in Burns - First publication of full data set shows use of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) eliminated autografting in 96% of burn sites treated w...
Mallinckrodt Announces Inclusion of Acthar® Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) Treatment Guidelines for Patients with Pulmonary Sarcoidosis -- Along with a Sarcoidosis Expert Panel Consensus Statement previously published in E...
ANI's business growth rate could be on the cusp of a rapid acceleration. Free cash flow generation is on the upswing. Stock valuations are pricing in stagnant results, mimicking rear-view mirror thinking. I like the technical chart pattern - a rising price could launch the quo...
Mallinckrodt Announces U.S. FDA Approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) -- First approved donor site-free alternative to autograft for deep partial-thickness burns designed to handle like an autograft and...
JodiJacobson/E+ via Getty Images The FDA has approved StrataGraft, a topical application that uses a patient's own skin cells to treat thermal burns. keratinocytes and dermal fibroblasts grown together to make a bi-layered construct known as a cellularized scaffold. StrataGraft is ...
The virtual event aims to promote the attainment of pre-launch excellence in strategic cross-functional alignment by optimizing publication strategies and supporting product approvals The three-day event adopts a half-day format to maximize retention and engagement It will feature two...
Without legal risks, Teva would be a compelling long, with ~200% upside potential if the company can meet 2023 targets, which I think is possible. However, legal risks, particularly the lack of a nationwide opioid settlement, exacerbate refinancing risks in 2023, making bankruptcy a m...
Mallinckrodt Presents Data Evaluating Acthar® Gel (Repository Corticotropin Injection) for the Treatment of Severe Keratitis at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting ‒ Phase 4 open-label study showed clinically important impro...
Mallinckrodt Presents Data Evaluating INOmax® (Nitric Oxide) Gas, for Inhalation in a Phase 4 Observational Registry in Neonates with Pulmonary Hypertension at the Pediatric Academic Societies (PAS) 2021 Virtual Meeting - Full results presented for Phase 4 observational reg...
News, Short Squeeze, Breakout and More Instantly...
MALLINCKRODT TO REPORT EARNINGS RESULTS FOR SECOND QUARTER 2022 AND PROVIDE BUSINESS UPDATE PR Newswire DUBLIN , Aug. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, announced today that it wil...
Mallinckrodt Emerges from Chapter 11 with Strengthened Balance Sheet and Enhanced Financial Flexibility PR Newswire Appoints Sigurdur Olafsson as President and Chief Executive Officer DUBLIN, Ireland , June 16, 2022 /PRNewswire/ -- Mallinckr...
Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome PR Newswire DUBLIN , June 13, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced the ...